Dublin, March 29, 2019 (GLOBE NEWSWIRE) -- The "Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids, 2019-2030" report has been added to ResearchAndMarkets.com's offering.
The Novel Technologies for Delivery of Proteins, Antibodies, and Nucleic Acids, 2019-2030 report features an extensive study of the current market landscape and the likely future adoption of such technologies, over the next twelve years.
Given their high target specificity and limited toxicity compared to small molecule drugs, biotherapeutics have revolutionized treatment paradigms across a myriad of clinical conditions, including metabolic disorders, cancers, neurological disorders, and autoimmune disorders. In fact, the extent of growth of such therapies can be gauged from the fact that more than 300 biopharmaceuticals have been approved between 2002 and 2018. In 2018, over 15 biological license applications (BLA) received approval.
Previously, in 2017, 12 new biologics were approved by the US FDA, which included antibodies (9), antibody-drug conjugates (1), and enzymes (2). Such products are inherently complex, and their full potential continues to remain untapped owing to an array of concerns associated with their development, manufacturing, and administration. Specifically, the challenges associated with the delivery of such drugs can be attributed to their large molecular weight, short half-lives, and instability in the gastrointestinal (GI) tract and intestinal lumen.
Owing to their susceptibility to enzymatic degradation, the parenteral route of administration is considered to be the most acceptable mode of delivery, enabling such drugs to directly enter the systemic circulation. However, parenteral administration often requires patients to visit healthcare centers or clinics for dosing. As a result, non-adherence to prescribed therapeutic regimens is rampant among end-users.
Despite these challenges, the demand for biologics is high because of their favorable safety profiles, greater systemic compatibility, and fewer side effects. As a result, medical researchers and therapy developers are actively attempting to identify and exploit alternative delivery strategies for such products; examples include aerosol generation systems, lipid nanoparticles, DNA-based delivery technologies, and brain shuttles (designed to facilitate increased drug penetration across the elusive blood-brain barrier).
Currently, several biopharmaceutical companies have undertaken initiatives to develop cell-specific drug delivery technologies and have superior formulation technologies, imparting improved release properties to drugs being delivered. Consequently, pharmaceutical developers are likely to witness a rise in available options for the delivery of their respective products in the foreseen future.
One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for novel technologies designed for the administration of proteins, antibodies, and nucleic acids. Based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2018-2030.
The report features likely distribution of the current and forecasted opportunity across the [A] type of therapeutic area (oncology and non-oncology), [B] route of administration (parenteral and non-parenteral), [C] key contributing technologies and [D] key geographical regions (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
The study features in-depth analysis, highlighting:
- A detailed assessment of the current market landscape of companies offering technologies for delivery of biotherapeutics, including information on their geographical location, types of biologics delivered (proteins, peptides, antibodies and nucleic acids), routes of administration used (parenteral, oral, transdermal / topical, inhalation and others) and impact on drug properties / patient compliance.
- A comprehensive competitiveness analysis of the drug delivery technologies captured in our report database, taking into consideration the supplier power (based on year of establishment) and key technology-related specifications, such as the type(s) of biologics delivered, the extent of the impact on drug properties, patient compliance and the route of administration.
- Elaborate profiles of prominent technology developers engaged in this domain, featuring a brief overview of the company, its financial performance (if available), information on its product portfolio, recent developments and a comprehensive future outlook. Additionally, the report includes profiles of certain technologies that emerged as relatively superior in our proprietary competitiveness analysis.
- An in-depth analysis of the various patents that have been filed and granted related to novel drug delivery technologies, till November 2018. It includes information on key parameters, such as patent type, publication year, issuing authority, CPC classification, emerging focus areas and leading industry / academic players (in terms of the size of the intellectual property portfolio).
- A detailed analysis of the partnerships and collaborations focused on technologies for the delivery of biotherapeutics, featuring a comprehensive set of analyses based on various parameters, such as the year of establishment, type of partnership, type of therapeutic areas, most active players and geographical location.
- A discussion on the upcoming opportunities in the field of biotherapeutic drug delivery that are likely to impact the evolution of this market in the coming years.
Key Topics Covered:
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. Executive Summary
3. Introduction
3.1. An Overview of Biopharmaceuticals
3.2. Demand for Biopharmaceuticals
3.3. Types of Biopharmaceuticals
3.3.1. Proteins and Peptides
3.3.2. Antibodies
3.3.3. Nucleic Acids
3.4. Common Routes of Administration for Biopharmaceuticals
3.4.1. Parenteral Delivery
3.4.1.1. Intravenous Route
3.4.1.2. Intramuscular Route
3.4.1.3. Subcutaneous Route
3.4.2. Non-Parenteral Delivery
3.4.2.1. Buccal / Sublingual Route
3.4.2.2. Intranasal Route
3.4.2.3. Inhalation / Pulmonary Route
3.4.2.4. Ocular Route
3.4.2.5. Oral Route
3.4.2.6. Rectal Route
3.4.2.7. Transdermal Route
3.5. Key Challenges Associated with Drug Delivery
3.6. Advanced Approaches for Delivery of Biotherapeutics
3.6.1. Muco-Adhesive Polymeric Systems
3.6.2. Nanoparticle-based Delivery Systems
3.6.3. Other Drug Delivery Technologies
3.7. Demand for Novel Drug Delivery Technologies
3.8. Concluding Remarks
4. Market Landscape
4.1. Chapter Overview
4.2. Novel Technologies for Proteins, Antibodies and Nucleic Acids: Overall Market Landscape
4.2.1. Analysis by Size of Developer Company
4.2.2. Analysis by Year of Establishment
4.2.3. Analysis by Type of Technology
4.2.4. Analysis by Type of Biologics Delivered
4.2.5. Analysis by Impact of Technology on Drug Properties / Patient Compliance
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Geographical Location of Developer Company
4.3. Grid Analysis: Distribution by Type of Biologics, Route of Administration and Drug Delivery Parameters
4.4. List of Drug Formulation Technologies
5. Product Competitiveness Analysis
5.1. Chapter Overview
5.2. Product Competitiveness Analysis: Key Assumptions and Methodology
5.2.1. Technologies of Companies Based in North America
5.2.2. Technologies of Companies Based in Europe
5.2.3. Technologies of Companies Based in Asia-Pacific
6. Technology Profiles
6.1. Chapter Overview
6.2. Intravail Technology
6.3. RapidMist
6.4. TheraKine Technology
6.5. Arestat Technology
6.6. DelSiTech Silica Matrix
6.7. ImSus Technology
6.8. PLEX Technology
6.9. ENHANZE Technology
7. Company Profiles: Drug Delivery Platform Providers
7.1. Chapter Overview
7.2. Aphios
7.3. Arbutus Biopharma
7.4. Camurus
7.5. ConjuChem
7.6. InnoCore Pharmaceuticals
7.7. LATITUDE Pharmaceuticals
8. Patent Analysis
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Patent Analysis
8.3.1. Analysis by Publication Year
8.3.2. Analysis by Issuing Authority / Patent Offices Involved
8.3.3. Analysis by CPC Classification
8.3.4. Emerging Focus Areas
8.3.5. Leading Players Based on Number of Patents
8.4. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Patent Benchmarking Analysis
8.4.1. Analysis by Patent Characteristics
8.4.2. Analysis by Geography
8.5. Novel Technologies for Proteins, Antibodies and Nucleic Acids: Patent Valuation Analysis
9. Recent Partnerships
9.1. Chapter Overview
9.2. Partnership Models
9.3. Novel Technologies for Proteins, Antibodies and Nucleic Acids: List of Partnerships and Collaborations
10. Market Sizing And Opportunity Analysis
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Information on Licensing Deals
10.4. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Overall Market, 2019-2030
10.5. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Region, 2019 and 2030
10.6. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Therapeutic Area, 2019 and 2030
10.7. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market Attractiveness Analysis by Therapeutic Areas
10.8. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Route of Delivery, 2019 and 2030
10.9. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Key Contributing Technologies, 2019 and 2030
11. Future Growth Opportunities
11.1. Chapter Overview
11.2. The Industry Has Recently Witnessed A Shift from Conventional Nanoparticle-Based Technologies to DNA-Based Solutions
11.3. Despite Extensive Research Efforts in this Domain, There is Still A Substantial Unmet Need Related To Drug Delivery Technologies For Neurodegenerative Disorders
11.4. The Oral Route of Delivery, Owing to its Capability to Ensure Therapy Adherence, Has Garnered Significant Attention in this Market
11.5. Impending Patent Expirations Have Prompted Many Players to Adopt Various Life Cycle Management Strategies to Sustain Revenue Generation Potential
11.6. The Larger Market Share is Currently with the Developed Regions, while Contributions from Technology Providers in the Asia Pacific are Expected to Increase in the Foreseen Future
12. Executive Insights
12.1. Chapter Overview
12.2. ArmaGen
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Mathias Schmidt, Chief Executive Officer
12.3. ICB International
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Ram Bhatt, Chief Executive Officer, Chairman and Founder
12.4. KAER Biotherapeutics
12.4.1. Company Snapshot
12.4.2. Interview Transcript: Donovan Yeates, Chief Executive Officer and Chief Scientific Officer, Chairman and Founder
13. Appendix 1: Tabulated Data
14. Appendix 2: List Of Companies And Organizations
- 4P Therapeutics
- Abbott Laboratories
- AbbVie
- Acuitas Therapeutics
- ADAMA
- Adhera Therapeutics
- Adimab
- ADOCIA
- Aegis Therapeutics
- Aerogen
- AIMM Therapeutics
- Ajinomoto Bio-Pharma Services
- Albireo Pharma
- Alchemia
- Alexion Pharmaceuticals
- Allergan
- ALRISE Biosystems
- Alteogen
- AMAG Pharmaceuticals
- Amarantus BioScience Holdings
- Amgen
- Antares Pharma
- Antibody Solutions
- Aphios
- Applied Molecular Transport
- Apricus Biosciences
- Aquarius Biotechnologies
- Aquestive Therapeutics
- Aradigm
- Arbutus Biopharma
- Arecor
- ArmaGen
- Ascendis Pharma
- Astellas Research Institute of America
- AstraZeneca
- Avadel Pharmaceuticals
- Bausch Health Companies
- Baxter International
- Bayer
- BBI Solutions
- BGN Technologies
- Bio-Path Holdings
- Bioasis Technologies
- BioCardia
- BioCorRx
- Biogen
- BiondVax Pharmaceuticals
- Biovail Laboratories
- Boehringer Ingelheim
- Brigham and Women's Hospital
- Bristol-Myers Squibb
- C-TRI
- Caisson Biotech
- Camurus
- CannScience Innovations
- Capsugel
- Catalent Pharma Solutions
- Cell Care Therapeutics
- Centre for Process Innovation
- Cerenis Therapeutics
- Chembio Diagnostics
- Chugai Pharmaceutical
- ConjuChem Biotechnologies
- CordenPharma
- Corium International
- CSL Behring
- Cureport
- Dauntless Pharmaceuticals
- Delpor
- DelSiTech
- Dendreon
- Diabetology
- Dicerna Pharmaceuticals
- Dr Reddy's Laboratories
- Eisai
- Elasmogen
- Eli Lilly and Company
- Elusys Therapeutics
- Emergent BioSolutions
- Emergent Technology
- Emisphere Technologies
- enGene
- Engineered BioPharmaceuticals
- Epeius Biotechnologies
- EuMederis Pharmaceuticals
- Evonik
- Excelse Bio
- Exicure
- Feldan Therapeutics
- Ferring Pharmaceuticals
- Flex
- Foresee Pharmaceuticals
- FUJIFILM Diosynth Biotechnologies
- Genentech
- Generex Biotechnology
- Genexine
- Genisphere
- Genmab
- GlaxoSmithKline
- Graybug Vision
- Green Cross Labcell
- Gritstone Oncology
- Halozyme Therapeutics
- Heron Therapeutics
- Hovione
- Human Stem Cells Institute
- ICB International
- Ichor Medical Systems
- ImClone Systems
- Indivior UK
- InnoCore Pharmaceuticals
- Inovio Pharmaceuticals
- Inserm
- InteRNA Technologies
- Invenra
- Ionis Pharmaceuticals
- Janssen Pharmaceuticals
- Jerini
- Johnson & Johnson
- KAER Biotherapeutics
- Kolon Life Science
- Kolon TissueGene
- Kurve Technology
- Kyowa Hakko Kirin
- Lankenau Institute for Medical Research (LIMR)
- LATITUDE Pharmaceuticals
- Lauren Sciences
- Longevity Biotech
- Lupin Pharmaceuticals
- Lyndra Therapeutics
- MannKind
- Matinas BioPharma
- Medesis Pharma
- MedImmune
- Merck
- Merrion Pharmaceuticals
- Merz Pharma
- MiNA Therapeutics
- Mitsubishi Tanabe Pharma
- MonoSol
- Monsanto
- Mountain View Pharmaceuticals
- MultiCell Technologies
- Mylan
- Nanexa
- NanoCarrier
- Nanomi
- National Institute of Neurological Disorders and Stroke
- NBE-Therapeutics
- Neurelis
- NHTherapeutics
- NOD Pharmaceuticals
- Novartis
- Novo Nordisk
- Novosom
- Nutriband
- Oakwood Labs
- Octapharma
- Ocular Therapeutix
- Oncotelic
- Opiant Pharmaceuticals
- OPKO Biologics
- Oramed Pharmaceuticals
- Orbis Biosciences
- Pacira Pharmaceuticals
- Peptineo
- Peptron
- PepVax
- Pfizer
- PharmaIN
- PhaseBio Pharmaceuticals
- Phylogica
- Pickwick Capital Partners
- PolyPid
- Precision NanoSystems
- Profectus BioSciences
- Prometheon Pharma
- Prometheus Laboratories
- Prothena
- Proxima Concepts
- Pulmatrix
- Purdue Pharma
- Rani Therapeutics
- Receptor Life Sciences
- Regeneron Pharmaceuticals
- Rett Syndrome Research Trust
- rEVO Biologics
- Rhythm Pharmaceuticals
- Roche
- Roivant Sciences
- RoverMed BioSciences
- San Diego Hospice and The Institute for Palliative Medicine
- Sanofi
- Savient Pharmaceuticals
- ScinoPharm
- Scripps Research
- Serina Therapeutics
- Seton Healthcare Family
- Shanghai Sunway Biotech
- Sibiono GeneTech
- Sierra Oncology
- SmooFi
- Solani Therapeutics
- Spark Therapeutics
- Strides Pharma Science
- SUDA Pharmaceuticals
- Swedish Orphan Biovitrum
- Synthelis
- Takeda Oncology
- Takeda Pharmaceutical
- Tamarisk Technologies Group
- Tarix Pharmaceuticals
- Teva Pharmaceutical Industries
- Teva Respiratory
- The Jordanian Pharmaceutical Manufacturing
- Theraclone Sciences
- TheraKine
- Thomas Jefferson University
- Transdermal
- UCB
- University of Maryland
- University of North Texas Health Science Center
- University of Pennsylvania
- Valerion Therapeutics
- Velocity Pharmaceutical Development
- Vical
- ViroPharma
- ViroVet
- Xenetic Biosciences
- XL-protein
For more information about this report visit https://www.researchandmarkets.com/r/20wjrd
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.